Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.11.2009 | Preclinical Study

Biological significance of allele specific loss of the p53 gene in breast carcinomas

verfasst von: Pia P. Wegman, Nashwan J. Marcus, Breezy Paul Malakkaran, Sten Wingren

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The p53 tumor suppressor gene has a central role in the defense against cancer, including breast cancer, and contains a polymorphic variant (Arg/Pro) at codon 72 that has been shown to have different biological properties regarding apoptosis and cell cycle arrest. Earlier studies have shown allele specific loss of heterozygosity (LOH) at this particular site and we aimed to investigate its biological relevance in codon 72 heterozygous breast cancer patients (i.e., survival and age of disease onset). 199 postmenopausal cases were analyzed for LOH using MegaBACE1000 and statistics was performed using Statistical Package for Social Sciences. LOH was found in totally 124 (62.3%) patients and the Pro allele (n = 103) was significantly more often deleted compared to the Arg allele (n = 21) (P = 0.001). Patients with LOH of the Arg allele were diagnosed at an earlier age (mean age 62.5 years) than those with loss of the Pro allele (mean age 69.2 years) (P = 0.011). LOH of the Arg allele was also associated with worse survival (P = 0.05). LOH in comparison to ROH correlated significantly with increased S-phase fraction. Tumor size, stage or number of positive lymph nodes was not related to LOH. Our results and earlier findings suggest a selective loss of the Pro allele during carcinogenesis that might confer a growth advantage for cancer cells. On the other hand, it appears to be more harmful for patients to loose the Arg allele since we found that loss of this allele was associated with earlier onset and worse prognosis.
Literatur
1.
Zurück zum Zitat Hollstein M, Sidrowsky D, Vogelstein B, Harris C (1991) p53 Mutations in human cancers. Science 253:46–53CrossRef Hollstein M, Sidrowsky D, Vogelstein B, Harris C (1991) p53 Mutations in human cancers. Science 253:46–53CrossRef
2.
Zurück zum Zitat Giaccia AJ, Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973–2983CrossRefPubMed Giaccia AJ, Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973–2983CrossRefPubMed
3.
Zurück zum Zitat Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemical and biologically. Mol Cell Biol 19:1092–1100PubMed Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemical and biologically. Mol Cell Biol 19:1092–1100PubMed
4.
Zurück zum Zitat Dumont P, Leu JI, Della AC, Pietra DL, Murphy G (2003) The codon72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed Dumont P, Leu JI, Della AC, Pietra DL, Murphy G (2003) The codon72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed
5.
Zurück zum Zitat Sullivan A, Syed N, Gasco M, Bergmaschi D, Trigiante G, Attard M, Hiller I, Farrel PJ, Smith P, Lu X, Crook T (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328–3337CrossRefPubMed Sullivan A, Syed N, Gasco M, Bergmaschi D, Trigiante G, Attard M, Hiller I, Farrel PJ, Smith P, Lu X, Crook T (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328–3337CrossRefPubMed
6.
Zurück zum Zitat Pim D, Banks L (2004) p53 Polymorphic variants at codon72 exerts different effects on cell cycle progression. Int J Cancer 108:196–199CrossRefPubMed Pim D, Banks L (2004) p53 Polymorphic variants at codon72 exerts different effects on cell cycle progression. Int J Cancer 108:196–199CrossRefPubMed
7.
Zurück zum Zitat Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sar G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds proline-rich region and modulate apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133–1141CrossRefPubMed Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sar G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds proline-rich region and modulate apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133–1141CrossRefPubMed
8.
Zurück zum Zitat Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, Smitten KV, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro 72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103CrossRefPubMed Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, Smitten KV, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro 72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103CrossRefPubMed
9.
Zurück zum Zitat Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 Codon72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389–392CrossRefPubMed Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 Codon72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389–392CrossRefPubMed
10.
Zurück zum Zitat Byuru N, Tigli H, Dalay N (2003) p53 Codon72 polymorphism in breast cancer. Oncol Rep 10:711–714 Byuru N, Tigli H, Dalay N (2003) p53 Codon72 polymorphism in breast cancer. Oncol Rep 10:711–714
11.
Zurück zum Zitat Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphism with the risk of Japanese breast cancer. Breast cancer 10:307–311CrossRefPubMed Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphism with the risk of Japanese breast cancer. Breast cancer 10:307–311CrossRefPubMed
12.
Zurück zum Zitat Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 codon72 polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203CrossRefPubMed Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 codon72 polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203CrossRefPubMed
13.
Zurück zum Zitat Mabrouk I, Baccouche S, Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764–770CrossRefPubMed Mabrouk I, Baccouche S, Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764–770CrossRefPubMed
14.
Zurück zum Zitat Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Oliveri F, Franceschi C (2003) Retention of the codon72 Arginine allele is associated with a reduction of disease-free and overall survival in Arginine/Proline heterozygous breast cancer patients. Clin Cancer Res 9:4860–4864PubMed Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Oliveri F, Franceschi C (2003) Retention of the codon72 Arginine allele is associated with a reduction of disease-free and overall survival in Arginine/Proline heterozygous breast cancer patients. Clin Cancer Res 9:4860–4864PubMed
15.
Zurück zum Zitat Schneider-Stock R, Boltz C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon72 Proline p53 and frequent mutational inactivation of retained Arginine allel in colorectal cancer. Neoplasia 6:529–535CrossRefPubMed Schneider-Stock R, Boltz C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon72 Proline p53 and frequent mutational inactivation of retained Arginine allel in colorectal cancer. Neoplasia 6:529–535CrossRefPubMed
16.
Zurück zum Zitat Mitra S, Banerjee S, Misra C, Singh RK, Roy A, Sengupta A, Panda CK, Roychoudhury S (2007) Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian population. J Clin Pathol 60:1040–1047CrossRefPubMed Mitra S, Banerjee S, Misra C, Singh RK, Roy A, Sengupta A, Panda CK, Roychoudhury S (2007) Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian population. J Clin Pathol 60:1040–1047CrossRefPubMed
17.
Zurück zum Zitat Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34CrossRefPubMed Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34CrossRefPubMed
18.
Zurück zum Zitat Kyndi M, Alsner J, Hansen LL, Sorensen F, Overgaard J (2006) LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 45:602–609CrossRefPubMed Kyndi M, Alsner J, Hansen LL, Sorensen F, Overgaard J (2006) LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 45:602–609CrossRefPubMed
19.
Zurück zum Zitat Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9(1):R7CrossRefPubMed Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9(1):R7CrossRefPubMed
20.
Zurück zum Zitat Brooks LA, Tidy JA, Gusterson B, Hiller L, O′Nions J, Gasco M, Marin MC, Farrel PJ, Kaelin W, Crook T (2000) Preferential retention of codon72 Arginine p53 in squamous cell carcinoma of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60:6875–6877PubMed Brooks LA, Tidy JA, Gusterson B, Hiller L, O′Nions J, Gasco M, Marin MC, Farrel PJ, Kaelin W, Crook T (2000) Preferential retention of codon72 Arginine p53 in squamous cell carcinoma of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60:6875–6877PubMed
21.
Zurück zum Zitat Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B (1997) The influence of the p53 codon72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239–245PubMed Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B (1997) The influence of the p53 codon72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239–245PubMed
22.
Zurück zum Zitat Papadakis ED, Soulitiz N, Spandidos DA (2002) Association of p53 codon72 Polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013–1018CrossRefPubMed Papadakis ED, Soulitiz N, Spandidos DA (2002) Association of p53 codon72 Polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013–1018CrossRefPubMed
23.
Zurück zum Zitat Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K (2000) p53 Polymorphism in human papillomavirus- associated esophageal cancer. Cancer Res 60:2753–2755PubMed Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K (2000) p53 Polymorphism in human papillomavirus- associated esophageal cancer. Cancer Res 60:2753–2755PubMed
24.
Zurück zum Zitat Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T (2002) p53 Mutation arising in Arg 72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8:1192–1198PubMed Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T (2002) p53 Mutation arising in Arg 72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8:1192–1198PubMed
25.
Zurück zum Zitat Marin M, Jost C, Brooks L, Irwin M, Nions J, Tidy J, James N, McGregor J, Harwood C, Yulug I, Vousdrn K, Allday M, Gusterson B, Ikawa S, Hinds P, Crook T, Kaelin W (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54CrossRefPubMed Marin M, Jost C, Brooks L, Irwin M, Nions J, Tidy J, James N, McGregor J, Harwood C, Yulug I, Vousdrn K, Allday M, Gusterson B, Ikawa S, Hinds P, Crook T, Kaelin W (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54CrossRefPubMed
26.
Zurück zum Zitat Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo R, Moriuchi T (2001) Inactivating of the remaining p53 allele or the alternate p73? Preferential selection of the Arg polymorphism in cancer with recessive p53 mutant but not transdominant mutants. Carcinogenesis 22:515–517CrossRefPubMed Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo R, Moriuchi T (2001) Inactivating of the remaining p53 allele or the alternate p73? Preferential selection of the Arg polymorphism in cancer with recessive p53 mutant but not transdominant mutants. Carcinogenesis 22:515–517CrossRefPubMed
27.
Zurück zum Zitat Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farell PJ, Smith P, Lu X, Crook T (2003) p53 Polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387–402CrossRefPubMed Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farell PJ, Smith P, Lu X, Crook T (2003) p53 Polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387–402CrossRefPubMed
28.
Zurück zum Zitat Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Gulida G, Rzyman W, Jassem J (2005) Increased risk of non-small cell lung cancer and frequency of somatic TP53 mutations in pro72 carrier of the arg72pro polymorphism. Lung cancer 52:9–14CrossRef Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Gulida G, Rzyman W, Jassem J (2005) Increased risk of non-small cell lung cancer and frequency of somatic TP53 mutations in pro72 carrier of the arg72pro polymorphism. Lung cancer 52:9–14CrossRef
29.
Zurück zum Zitat Hu Y, McDermott M, Ahrendt S (2005) The codon 72 proline allele is associated with p53 gene mutations in non-small cell ung cancer. Clin Cancer Res 11:2502–2509CrossRefPubMed Hu Y, McDermott M, Ahrendt S (2005) The codon 72 proline allele is associated with p53 gene mutations in non-small cell ung cancer. Clin Cancer Res 11:2502–2509CrossRefPubMed
30.
Zurück zum Zitat Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, Xie Y (2008) Effect of codon 72 genotype on breast cancer survival depends on p53 status. Int J Cancer 122:2761–2766CrossRefPubMed Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, Xie Y (2008) Effect of codon 72 genotype on breast cancer survival depends on p53 status. Int J Cancer 122:2761–2766CrossRefPubMed
31.
Zurück zum Zitat Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfini D, Fabbri F, Ulivi P, Brigliadori G, Amodori D, Bonafe M (2008) Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumor Biol 29:145–151CrossRef Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfini D, Fabbri F, Ulivi P, Brigliadori G, Amodori D, Bonafe M (2008) Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumor Biol 29:145–151CrossRef
32.
Zurück zum Zitat Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333CrossRefPubMed Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333CrossRefPubMed
33.
Zurück zum Zitat Nordgard S, Alnas G, Hihn B, Lingjarde OC, Liestol K, Tsalenko A, Sorli T, Lonning PE, Borresen AL, Kristensen V (2008) Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer 123:577–585CrossRefPubMed Nordgard S, Alnas G, Hihn B, Lingjarde OC, Liestol K, Tsalenko A, Sorli T, Lonning PE, Borresen AL, Kristensen V (2008) Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer 123:577–585CrossRefPubMed
Metadaten
Titel
Biological significance of allele specific loss of the p53 gene in breast carcinomas
verfasst von
Pia P. Wegman
Nashwan J. Marcus
Breezy Paul Malakkaran
Sten Wingren
Publikationsdatum
01.11.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0212-1

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.